CTD Holdings, Inc. , a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that the European Medicines Agency and European Commission approved transfer of the Orphan Drug Designation for Trappsol Cyclo to CTD's European partner, Medical Need Europe , from Sue and David French and their Niemann Pick Research Foundation. MNE, which is the exclusive distributor of Trappsol Cyclo in Europe, will be the official sponsor of the European orphan drug designation on behalf of CTD.
http://ift.tt/1PftGTg
http://ift.tt/1PftGTg
No comments:
Post a Comment